Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Anti-inflammatory Effect of Puerarin through Optimized Release and Bioavailability via PDLG-Loaded Nanoparticles.

Biological & pharmaceutical bulletin·2025
Same author

<i>Murraya koenigii</i> (L.) Spreng. as a Natural Intervention for Diabesity: A Review.

Current pharmaceutical design·2024
Same author

MsrA Efflux Pump Inhibitory Activity of Piper cubeba L.f. and its Phytoconstituents against Staphylococcus aureus RN4220.

Chemistry & biodiversity·2020
Same journal

PROTAC-Mediated Targeting of PARP via CRBN: Mechanistic Insights, Resistance Challenges, and Therapeutic Advancements.

Mini reviews in medicinal chemistry·2026
Same journal

Recent Advancements in the Development of Heterocyclic Scaffolds as Potential Anti-cancer Agents Targeting EGFR and VEGFR-2.

Mini reviews in medicinal chemistry·2026
Same journal

Exploring the Anticancer Potential of Synthetic β-Carboline Derivatives: A Comprehensive Systematic Review.

Mini reviews in medicinal chemistry·2026
Same journal

KIF20A in Human Malignancies: Oncogenic Mechanisms and Therapeutic Targeting Strategies.

Mini reviews in medicinal chemistry·2026
Same journal

Phytocompound-loaded Biomaterial-based Scaffolds: Emerging Strategies for Wound Healing Applications.

Mini reviews in medicinal chemistry·2026
Same journal

Bioprospecting of Natural Products as Sources of New Multitarget Therapies.

Mini reviews in medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Recent developments in antitubercular drugs.

Pallavi Ahirrao1

  • 1Type V/11, NIPER Campus, Sector-67, SAS Nagar (Mohali)- 160062, Punjab, India. pahirrao11@gmail.com

Mini Reviews in Medicinal Chemistry
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

This review covers current tuberculosis (TB) drugs and novel agents like diarylquinolines. It explores future TB drug development targeting Mycobacterium tuberculosis, considering structure-activity relationships.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Area of Science:

  • Microbiology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Tuberculosis (TB) remains a significant global health challenge, necessitating continuous development of effective treatments.
  • Existing TB drug regimens face challenges including drug resistance and lengthy treatment durations.

Purpose of the Study:

  • To review current tuberculosis (TB) drugs, detailing their advantages and disadvantages.
  • To highlight promising new anti-TB agents, including diarylquinolines, oxazolidinones, and nitroimidazoles.
  • To discuss future directions in antitubercular drug development, focusing on novel targets and structure-activity relationships (SAR).

Main Methods:

  • Literature review of current and emerging anti-TB therapies.
  • Analysis of drug mechanisms, efficacy, and limitations.
  • Exploration of structure-activity relationships for key anti-TB drug classes.

Main Results:

  • Current TB drugs have established efficacies but also limitations, driving the need for new therapies.
  • Emerging drug classes like diarylquinolines show significant promise in preclinical and clinical studies.
  • Understanding Mycobacterium tuberculosis targets and SAR is crucial for designing next-generation anti-TB agents.

Conclusions:

  • A diverse pipeline of novel anti-TB agents is under development, offering hope for improved treatment outcomes.
  • Targeting specific pathways in Mycobacterium tuberculosis and optimizing drug structures are key strategies for future drug discovery.
  • Continued research into novel anti-TB agents and drug development is essential to combat the global TB burden.